Abstract: A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provide high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold is typically formed from non-degradable material and will be modified to expand and/or uncage after deployment.

Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including at least one of a chelating agent, a direct factor Xa inhibitor, a direct factor IIa inhibitor, and a factor XI/XIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent a target site in the patient's body. The therapeutic composition is formulated to release the one or more active substances to the target site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation. Delayed or other controlled release of the therapeutic composition from the structure may be provided.

Abstract: Balloon catheters, sleeves, cages, and endoluminal prostheses are provided with stress-applying and spacing features coupled to expandable surfaces thereof. The stress-applying features may have blunt and/or rounded contact regions which contact tissue or calcified regions in the vasculature. The contact regions dent or fracture occlusive material on the wall of a vascular lumen and/or patient valve leaflets when expanded. The spacing features permit blood, drug, and contrast perfusion past structures expanded in the vasculature, particularly balloon catheters.

Abstract: An aspiration catheter includes a catheter body having a proximal end, a distal end, and an aspiration lumen therebetween. A distal segment comprising an expandable distal tip of the aspiration catheter comprises a membrane and an expandable supporting structure, such as a scaffold, configured to radially expand the expandable distal tip. The expandable supporting structure may include supporting elements and other features which increase resistance to collapse of the expandable membrane under vacuum or negative pressure applied to aspirate clot through the aspiration lumen in the expanded configuration.

Abstract: An aspiration catheter for removing clot from a blood vessel includes a catheter body having a scaffold extending distally from a distal end of the body. An aspiration lumen runs from the distal end to a proximal end of the body, and a central clot-receiving passage in the scaffold is contiguous with the aspiration lumen of the catheter body. A vacuum-resistant membrane covers the scaffold and establishes a clot aspiration path from a distal end of the scaffold to a proximal end of the aspiration lumen, in the catheter body so that applying a vacuum to the proximal end of the aspiration lumen can draw clot into the central clot-receiving passage. The scaffold may have a comical configuration, a cylindrical configuration, or a combination thereof, and at least a distal portion of the scaffold is radially expandable from a delivery configuration to an extraction configuration.

Abstract: A biodegradable stent prosthesis formed from a degradable material, having a plurality of luminal, abluminal, and side surface regions, wherein a surface portion extending between the abluminal and luminal surface region of at least some structural elements is convex.

Abstract: Balloon catheters, sleeves, cages, and endoluminal prostheses are provided with stress-applying and spacing features coupled to expandable surfaces thereof. The stress-applying features may have blunt and/or rounded contact regions which contact tissue or calcified regions in the vasculature. The contact regions dent or fracture occlusive material on the wall of a vascular lumen and/or patient valve leaflets when expanded. The spacing features permit blood, drug, and contrast perfusion past structures expanded in the vasculature, particularly balloon catheters.

Abstract: A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provide high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold is typically formed from non-degradable material and will be modified to expand and/or uncage after deployment.

Abstract: The disclosure provides biodegradable implantable devices such as a stent comprising a biodegradable polymeric material wherein the polymeric material is treated to control crystallinity and/or Tg. The stent is capable of expanding at body temperature in a body lumen from a crimped configuration to a deployed diameter and will have sufficient strength to support a body lumen when expanded.

Abstract: An aspiration catheter includes a catheter body having a proximal end, a distal end, and an aspiration lumen therebetween. A distal segment comprising an expandable distal tip of the aspiration catheter comprises a membrane and an expandable supporting structure, such as a scaffold, configured to radially expand the expandable distal tip. The expandable supporting structure may include supporting elements and other features which increase resistance to collapse of the expandable membrane under vacuum or negative pressure applied to aspirate clot through the aspiration lumen in the expanded configuration.

Abstract: Devices, formulations, compositions, and methods are provided for inhibiting an inflammatory ophthalmic disease or eye condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor II inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory ophthalmic disease or condition in the patient’s eye(s). The therapeutic composition may be formulated for delivery to the patient by via injection, an implant, an eye drop, an emulsion, a suspension, an ointment, a nanomicelle, a nanoparticle, a nanosuspension, a liposome, an in-situ gel, a contact lens, or a microneedle or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.

Abstract: A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provide high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold is typically formed from non-degradable material and will be modified to expand and/or uncage after deployment.

Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.

Abstract: Devices, compositions, and methods are provided for inhibiting an inflammatory, fibrotic, and/or clot formation for pulmonary disease or condition in a patient. A therapeutic composition comprising a direct factor Xa inhibitor and/or a direct factor IIa inhibitor is provided. A therapeutically effective dose of the therapeutic composition is delivered to a site of the inflammatory, fibrotic, and/or clot formation pulmonary disease or condition in the patient's lung(s). The therapeutic composition may be formulated for delivery to the patient by inhalation, ventilation, instillation, ultrasound, vibration, injection, or the like. The therapeutic composition may include one or more additional therapeutically active substances and/or one or more additional pharmaceutical agents.

Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Abstract: Clot aspiration systems intended for removing clot from a blood vessel include an aspiration assembly which will have two or more of the following components: an aspiration catheter, an inner catheter, an intermediate catheter, and an outer catheter, the latter typically being a guiding or other sheath. A transition structure is coupled to a distal end of the aspiration assembly to cover or fill an open distal end of one or more of the components of the aspiration assembly. The transition structure may be configured to facilitate introduction of the aspiration catheter into the patient's vasculature and/or advancement of the aspiration catheter through the vasculature to a target site, such as a cerebral target site which may be occluded with clot, thrombus, or other occlusive material.

Abstract: A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provide high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold is typically formed from non-degradable material and will be modified to expand and/or uncage after deployment.

Abstract: A system for reshaping a valve annulus includes an elongate template having a length along a longitudinal axis and at least one concavity in a generally lateral direction along said length. The pre-shaped template is positioned against at least a region of an inner peripheral wall of the valve annulus, and at least one anchor on the template is advanced into a lateral wall of the valve annulus to reposition at least one segment of the region of the inner peripheral wall of the valve annulus into said concavity. In this way, a peripheral length of the valve annulus can be foreshortened and/or reshaped to improve coaptation of the valve leaflets and/or to eliminate or decrease regurgitation of a valve.

Abstract: Balloon catheters, sleeves, cages, and endoluminal prostheses are provided with stress-applying and spacing features coupled to expandable surfaces thereof. The stress-applying features may have blunt and/or rounded contact regions which contact tissue or calcified regions in the vasculature. The contact regions dent or fracture occlusive material on the wall of a vascular lumen and/or patient valve leaflets when expanded. The spacing features permit blood, drug, and contrast perfusion past structures expanded in the vasculature, particularly balloon catheters.